Discovery Matters

Explore the potential of artificial intelligence (AI) and machine learning to revolutionize biomedical research and make personalized healthcare a reality.

Tune in to Discovery Matters to see how AI and machine learning will be the future of biomedical research. Featuring interviews with Professor Kourosh Saeb-Parsy and Dr Namshik Han — leaders in the AI and biotech space — this episode delves into the significance of advanced technology for unlocking discoveries in transplantation, understanding the causes of diseases, precision medicine, and more.

This AI learnt language by seeing the world through a baby’s eyes

Computational phylogenetics reveal histories of sign languages

Let’s explore the world of antibody drug conjugates (ADCs) and their potential for improving human health. Our two guests—Principal Investigator Sasha Ebrahimi from GSK and oncologist Dr. Paolo Tarantino—discuss the development and advantages of ADCs, and how they can be used to personalize treatments for cancer and other illnesses. Sasha explains how ADCs combine the targeting capabilities of antibodies with the cytotoxic effects of drugs, while Dr. Tarantino delves into his research with breast cancer and immunotherapies. Learn more about the possibilities of ADCs in this insightful episode of Discovery Matters.

Keywords: antibody drug conjugates, adc, chemotherapy, antibodies, cancer, oncology, patient, breast cancer.

Discovery Matters is back with our best episodes and insights from the past year. Dodi and Conor re-explore some cutting-edge ideas and technologies pushing the frontiers of science and medicine forward. We look back on some of our favorite episodes including therapies such as psychedelic drugs, the sentience of brain cells, and the potential of marine microbes to fight cancer. They explore the potential of DNA to create medicine, the use of organoids in drug testing, and the use of cryopreservation for cell therapies. Join us as we uncover newer and better ways of improving health through science. Find out why Discovery Matters to you and the world by tuning into this episode.

Join Conor and Dodi in the latest episode of Discovery Matters, as they explore the wonders of ground-breaking scientific discoveries from multidisciplinary collaboration. MIT's Professor Pete Dedon expresses how multidisciplinary approaches and unique combinations of experiences can help to produce unexpected results. Professor James Evans of the University of Chicago then brings in the concept of surprise and hypergraphs to uncover the connections between different fields of knowledge. With insights from their guests, the latest episode of Discovery Matters dives deep into the mechanics behind groundbreaking discoveries. Jump in and listen to discover new ways to think about innovations and uncover the next amazing breakthrough!

Keywords: multidisciplinary, ideas, papers, surprise, science, combinations, teams, antibiotics, compounds, infectious diseases, malaria, space, serendipity.

Let’s explore the world of organoids and their potential to revolutionize disease treatment. Joined by Matthias Zilbauer and Roisin Owens, we look at the interplay of the gut-brain axis with organic electronic materials. Dive into the advances in organoid and microbial models used to develop treatments for illnesses such as Irritable Bowel Syndrome (IBS), Crohn’s Disease, and Ulcerative Colitis. Join Dodi and Conor to discover how bioengineering could change our understanding of health and disease - and our lives.

Transcript

Show notes

Shi, F., Evans, J. Surprising combinations of research contents and contexts are related to impact and emerge with scientific outsiders from distant disciplines. Nat Commun 14, 1641 (2023). https://doi.org/10.1038/s41467-023-36741-4.

Moon landing: India’s home-grown tech cut the costs (nature.com)

Keywords: microbiome, patient, model, cells, tissue, disease, gut, biological systems, microbes, biology, pediatric gastroenterology, science, organoids

In this episode of Discovery Matters, we discuss the exciting potential of lipid nanoparticles (LNPs) to deliver genetic material and therapeutics to target cells and tissues. We are joined by Lloyd Jeffs, Senior Director of Biopharma Services at Precision NanoSystems, and Prof Dan Peer, Director of the Laboratory of Precision Nanomedicine at Tel Aviv University. Dan shares how his team has developed siRNA LNPs to deliver treatment more efficiently for ovarian cancer patients. From Dan's unique perspective, learn why this technology is cutting-edge, and why it may help defeat one of mankind’s biggest enemies— cancer.

Transcript

Show notes

Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells | Science Advances

Neuroscientists decoded a Pink Floyd song using people’s brain activity (sciencenews.org)

Nutrients | Free Full-Text | Does Pizza Consumption Favor an Improved Disease Activity in Rheumatoid Arthritis? (mdpi.com)

Keywords: ovarian cancer, nanoparticles, lipid nanoparticles, genomic medicine, tumour, nucleic acids, cells, chemotherapy, drug, mrna, patients, sirna, rna.

Challenges of improving access to healthcare in developing countries - it's a conversation we need to have. With the help of Dr Jerome Kim, Director General of the International Vaccine Institute, we discuss vaccination and immunization programs as a key aspect of public health and global development – especially in developing nations, where access to life-saving medicines is often limited or non-existent. Karen Heichman, Deputy Director of Diagnostics, Bill and Melinda Gates Foundation, takes us on a journey of the critical role of diagnostics in the fight against diseases.

Through a discussion of combination therapies, Dodi and Conor delve into the mysterious power of the human microbiome, and antimicrobial resistance. With evidence of the microbiome being a key factor in fighting diseases, this episode highlights the importance of understanding and treating the microbiome and its potential to improve lives. Tune in to find out more and explore the possibilities of the microbiome with Dr Saman Maleki, and the power of serendipity with Prof Pete Dedon!

Transcript

Show notes

Routy, B., Lenehan, J.G., Miller, W.H. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med 29, 2121–2132 (2023).

A novel combination therapy counters antibiotic-resistant Mycobacterium abscessus infections (MIT news)

'Blight' warns that a future pandemic could start with a fungus (sciencenews.org)

Hildebrandt, T., Peyser, D. The gut microbiome in anorexia nervosa. Nat Microbiol 8, 760–761 (2023).

Keywords: microbiome, patients, immunotherapy, immune system, cancer, study, people, combination therapy, tumor, immuno-oncology, fungus, fecal transplant, anorexia nervosa, oncology, higher bmi

In this episode, we dive into the potential of liquid biopsies as a method to detect deadly diseases. We speak with three experts – Marta Herreros, Rik Bryan, and Doug Ward – to learn more about the non-invasive nature of liquid biopsies and the process of detecting biomarkers within a patient sample. Rik and Doug discuss their GALEAS Bladder test, which can identify key mutations present in 96% of bladder cancer patients. Tune in to learn more about the potential of liquid biopsies and the importance of early detection!

Transcript

Show notes

Keywords: bladder cancer, patient, liquid biopsy, urine, cells, bladder, urine test, urine sample, mutations, tumor, DNA, cancer, clinical trials, sequencing, samples, biomarkers.

Why do China and US have different government regulations? Why can’t we do business above the fray?

These are just some of the struggles biopharma executives report impacting their business. Our guests are of the same view – the industry needs fixing.

Yingke He, CEO and Co-Founder of Forecyte Bio, explains how China's industrialized experience is limited and in its early stages compared to the US.

Listen to this episode to understand the industry tensions and areas showing promise.

Transcript

Show notes

The Biopharma Resilience Index - Biopharma Resilience | Cytiva (cytivalifesciences.com)

Pessimists Archive - Pessimists Archive

Caesarean babies and their mother’s microbiome - 'Vaginal seeding' boosts the development of babies born by C-section | New Scientist

Keywords: talent, industry, manufacturing, collaboration, pandemic, therapies, challenges, government, regulators, biopharma resilience index, policies, solutions, companies, China, genomic medicine, cell and gene therapy.